Evidence map›Paper›PMID 41363670›Full record

ReviewEuropean surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes2026

Desensitization Strategies in Immunized Heart Transplant Recipients.

Adelheid Goerler, Sophie Kruszona, Khalil Aburahma, Nunzio Davide de Manna, Jawad Salman, Arjang Ruhparwar, Murat Avsar, Bastian Schmack, Fabio Ius

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Adelheid GoerlerDepartment of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Sophie KruszonaDepartment of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Khalil AburahmaDepartment of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Nunzio Davide de MannaDepartment of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Jawad SalmanDepartment of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Arjang RuhparwarDepartment of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Murat AvsarDepartment of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Bastian SchmackDepartment of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Fabio IusDepartment of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ius.fabio@mh-hannover.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAllosensitization, defined as the presence of anti-HLA antibodies before transplantation, prolongs the waiting list time and increases the waiting list mortality in patients awaiting heart transplantation. Treatment protocols have been developed to reduce the load of preformed anti-HLA antibodies (pfDSAs), defined as desensitization, and allow safe transplantation across the anti-HLA antibody barrier. Aim of this review was to give an overview on the actual desensitization strategies in heart transplantation. SUMMARY: Desensitization can be performed before transplantation or at the time of transplantation when a donor offer becomes available. Treatment protocols should include drugs and interventions that clear pfDSA, target antibody production, and mitigate antibody-mediated graft damage. By now, several transplant centers have developed their own protocols, with optimal graft survival, freedom from antibody-mediated rejection and from coronary allograft vasculopathy, without any significant adverse events. The evolution of the immunoassays for pfDSA detection has allowed a better precision in pfDSA characterization, such as measurement of titer and complement-binding capacity. These refinements have permitted crossing acceptable pfDSA without any need of desensitization. KEY MESSAGES: Crossing the HLA barrier is feasible and safe in heart transplantation. The complexity and redundancy of the immune pathways requires the identification of the appropriate therapy for each patient. Desensitization protocols should include more than one drug and intervention.

Indexed as

Desensitization, ImmunologicHeart TransplantationHLA AntigensGraft RejectionHumansHLA AntigensDesensibilizationHeart transplantationPreformed anti-HLA donor-specific antibodies

Identifiers

PMID41363670
PMCPMC12726855

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.